PCN67 COST UTILITY ANALYSIS OF ALEMTUZUMAB COMPARED TO CHLORAMBUCIL IN UNTREATED PATIENTS WITH HIGH-RISK (17P-) CHRONIC LYMPHOCYTIC LEUKEMIA IN THE UNITED KINGDOM
Nov 1, 2008, 00:00
10.1016/S1098-3015(10)66603-X
https://www.valueinhealthjournal.com/article/S1098-3015(10)66603-X/fulltext
Title :
PCN67 COST UTILITY ANALYSIS OF ALEMTUZUMAB COMPARED TO CHLORAMBUCIL IN UNTREATED PATIENTS WITH HIGH-RISK (17P-) CHRONIC LYMPHOCYTIC LEUKEMIA IN THE UNITED KINGDOM
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)66603-X&doi=10.1016/S1098-3015(10)66603-X
First page :
Section Title :
Open access? :
No
Section Order :
438